Afamelanotide vs Melanotan II.

Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I. It is formulated as a slow-release bioresorbable implant (Scenesse, Clinuvel) placed subcutaneously roughly every two months. Its approved use is not cosmetic tanning but photoprotection: increasing the amount of pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited condition causing severe phototoxic pain. It is one of the very few peptide analogs of alpha-MSH to complete formal Phase 3 development and gain regulatory approval. It is grouped under cosmetic here only because it acts on skin pigmentation pathways; clinically it is a photoprotective orphan drug.

Melanotan II (MT-II) is a synthetic, cyclic heptapeptide analog of the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed at the University of Arizona in the late 1980s and 1990s as part of a program designing protease-resistant "superpotent" melanotropins; the related linear analog melanotan I became the approved drug afamelanotide (Scenesse). Unlike afamelanotide, Melanotan II itself was never approved as a medicine and today circulates almost exclusively as an unlicensed product sold online for cosmetic "tanning" and as a libido agent.

Afamelanotide is an agonist at melanocortin-1 receptors (MC1R) on epidermal melanocytes. Activating MC1R stimulates production of eumelanin, the darker, more photoprotective form of melanin, independent of ultraviolet exposure. Increased eumelanin absorbs and scatters visible and UV light, reducing the free-radical and phototoxic response that causes pain in EPP, where protoporphyrin IX accumulates and is activated by light. The analog is more potent and longer-acting than native alpha-MSH because of amino-acid substitutions that resist enzymatic degradation. Additional antioxidant and anti-inflammatory melanocortin effects have been proposed but are less well characterized.

Melanotan II is a non-selective agonist of the melanocortin receptor family, binding MC1R, MC3R, MC4R and MC5R rather than selectively targeting MC1R. Activation of MC1R on cutaneous melanocytes stimulates the cAMP pathway and shifts melanin synthesis toward darker eumelanin, producing skin darkening that, unlike a UV tan, can occur with reduced sun exposure. Its central effects on sexual arousal and appetite are attributed mainly to MC4R (with possible MC3R contribution) in the hypothalamus and related circuits, while nausea, flushing and yawning also arise from this broad central melanocortin activation. The cyclic lactam structure makes it markedly more resistant to enzymatic degradation and more potent and longer-acting than native alpha-MSH.

Approval rested on randomized, placebo-controlled trials in EPP. In the pivotal randomized controlled trial published in the New England Journal of Medicine (Langendonk, Balwani et al., 2015), patients receiving afamelanotide implants recorded more total hours of pain-free sunlight exposure than those on placebo across parallel European and U.S. studies. The FDA summary describes a European trial in which the afamelanotide group spent roughly 64 hours in direct midday sunlight on pain-free days versus about 41 hours for placebo over 180 days, with a second study of similar design over 270 days. Effect sizes were statistically significant but modest in absolute terms, and outcomes relied on patient-recorded diaries. Long-term extension and post-marketing data continue to track durability and safety. The design carries specific caveats. Both pivotal studies were sponsored by the manufacturer, enrolled small populations because EPP is a rare disease, and used a patient-reported diary of time in sunlight as the primary endpoint rather than an objective measurement of light exposure or an adjudicated clinical outcome. Blinding is difficult to maintain with an agent whose visible effect is skin darkening, so participants and investigators could often infer allocation, a recognized source of bias in subjective endpoints. Later work has tried to address the measurement problem directly by recording light exposure objectively in EPP patients (Molecular Genetics and Metabolism, 2022). Pharmacokinetic and pharmacodynamic characterization of the implant and its dermatologic uses has been reviewed separately (Clinical Pharmacokinetics, 2017). What the EPP approval establishes is narrow. It shows that a slow-release implant of a stable alpha-MSH analog, given under physician supervision to adults with a specific inherited photosensitivity disorder, increases self-reported pain-free daylight time versus placebo over months. It does not establish efficacy or safety for cosmetic tanning, for skin cancer prevention, for any other photosensitivity condition, or for self-administered injectable products. Evidence for the widely marketed tanning use of Melanotan I is not from these regulated trials and is not supported to the same standard. Melanotan II, a different and unapproved analog sold online, has never completed a comparable regulated program at all.

Human data on Melanotan II is limited to small, early-phase academic studies and a large body of case reports; no Phase 2/3 program was ever completed and it has never been tested in large controlled trials. The best-documented human work is on erectile function: a 1998 double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction (Wessells et al., J Urol) and a 2000 study in men with organic erectile dysfunction (Urology) reported that subcutaneous Melanotan II initiated erections, accompanied by frequent nausea and yawning. Its tanning rationale rests on MC1R pharmacology and on the broader melanotan development program (Hadley et al., 1998), but rigorous controlled efficacy/safety data for cosmetic tanning in humans is essentially absent. Most contemporary human evidence comes from adverse-event case reports, including systemic toxicity with rhabdomyolysis (Clinical Toxicology, 2012) and dermatologic changes, so claims of benefit substantially outrun the controlled-trial evidence.

In EPP trials the most common adverse effects were implant-site reactions, headache, nausea, fatigue, and darkening of skin and pre-existing moles (expected from increased melanin). Because it drives pigmentation, regular full-skin and mole monitoring is advised, and the drug does not itself protect against UV-induced skin cancer. The trials that supported approval were small and ran for months rather than years, so long-term questions remain open: whether sustained melanocortin receptor stimulation influences melanocytic lesion behavior or melanoma risk over decades has not been resolved, which is one reason dermatologic surveillance is built into how the implant is used. Reviews of eruptive melanocytic nevi discuss the range of reported triggers, including drug exposures, and illustrate why new or changing pigmented lesions are treated as a monitoring priority in this setting. Unregulated Melanotan products sold online for tanning are a distinct safety concern: they are not the approved implant, may be contaminated or mis-dosed, and injectable use has been linked in case reports to nausea, blood-pressure changes, and changes in moles. These products bypass every control that applies to the licensed implant, which is manufactured to pharmaceutical standards, inserted by a trained physician, and dispensed only through certified prescribers under a specific rare-disease indication. Melanotan II in particular is an unapproved compound with no completed regulated trial program, sold with no verified content or sterility, and case reports describing adverse events after its use exist in the dermatology literature. This entry is educational and does not provide dosing guidance.

Commonly reported short-term effects in humans include nausea, vomiting, facial flushing, spontaneous yawning and stretching, appetite suppression, darkening of existing moles, and spontaneous erections or priapism in men. More serious documented harms from unregulated use appear in case reports: rhabdomyolysis and systemic toxicity, and a recurring concern about changes to melanocytic naevi (new and darkening moles, atypical naevi) with multiple published cases of melanoma reported in users, though causality has not been established and confounding by concurrent UV/tanning-bed exposure is a major limitation. Because the product is unlicensed and typically self-injected from non-pharmaceutical sources, contamination, mislabeling, dosing errors and sterility problems are additional, poorly quantified risks. This entry intentionally gives no doses or protocols; anyone considering use should consult a clinician, and dermatology bodies advise against use.

The FDA approved Scenesse (afamelanotide) in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, with Orphan Drug and Priority Review designations; the European Medicines Agency had authorized it earlier (2014). It is a prescription implant administered by a trained physician. Melanotan-branded tanning products are not approved and are considered unapproved drugs in many jurisdictions.

Melanotan II is not approved by the FDA or any major regulator for any indication and is not legally marketed as a medicine; products sold online are unlicensed. Regulators including the US FDA, the UK MHRA and Australia's TGA have issued consumer warnings against it. The distinct linear analog melanotan I (afamelanotide, Scenesse) is separately FDA- and EMA-approved, but only for erythropoietic protoporphyria, not for tanning.